Penn and CHOP investigators reported ongoing meaningful clinical benefit from a base-editing CRISPR intervention delivered via expanded access in an infant with CPS1 deficiency, emphasizing that the case is not a “cure” and was not a randomized trial. The update described improved ability to eat a normal protein-filled diet, with plans to potentially delay liver transplant until older. Lead scientist Kiran Musunuru underscored that the effort was an expanded access IND built as clinical care for a single patient rather than conventional clinical research, even as it fueled interest in the broader base-editing race. The framing matters for industry observers tracking how regulators, payers, and clinical trial designers will interpret case-level benefits versus trial-level efficacy. The story also reiterates that competing base-editing platforms—such as those in clinical trials for other disorders—are arriving with different evidence standards. For the sector, the key near-term question remains how quickly expanded access precedents can translate into scalable, trial-tested regimens.